Clinical trial · Interventional
Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention
Essential Oils Effect on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer: A Mixed Methods Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate an oil blend with active ingredients for the reduction in chemotherapy-induced peripheral neuropathy in people with breast cancer. Half of the participants will receive the oil blend with active ingredients and the other half will receive a placebo (an oil blend with no active ingredients). One-fourth of the people will also take pictures of their life with chemotherapy-induced peripheral neuropathy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Peripheral Neuropathies | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EOI | Other | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- EOI
- description
- 10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha x piperita, and Rosmarinus officinalis ct. cineole in Simmondsia chinensis
- interventionNames
- Other: EOI
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Simmondsia chinensis
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)
- timeFrame
- baseline and weekly for 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of breast cancer * chronic CIPN symptoms in one or both lower extremities * three months or greater since last chemotherapy treatment * mean SF-MPQ-2 score of greater than or equal to three * a prognosis of greater than six months Exclusion Criteria: * non-English-speaking * blindness * pregnancy * breastfeeding * allergy to EOI or Peru balsam (cross-allergen) * illegal substance usage * history of severe skin reactions * non-intact skin on lower extremities * history of lower extremity trauma or amputation * current use of aromatherapy/Essential Oils * asthma or reactive airway disease triggered by constituents of EOI * history of mental illness or chronic depression * the following co-morbidities: G6PD deficiency, inherited peripheral neuropathy, active herpes varicella-zoster, herpes simplex virus, alcoholic neuropathy, repetitive stress or entrapment neuropathy, peripheral vascular disease, and multifocal mononeuropathy.
References
Publications (0)
Data not yet available